Adjuvante und additive Therapie beim Pankreaskarzinom View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2003-03

AUTHORS

J.P. Neoptolemos, M. G.T. Raraty, P. Ghaneh, H. Hickey, D.D. Stocken, J. A. Dunn, H. Friess, M.W. Büchler

ABSTRACT

Recent advances have been made in the treatment of pancreas cancer.Specialized pancreas centres have reported an increasing rate of resections with reduced postoperative mortality. On account of the highly aggressive nature of pancreas cancer, there is a great challenge in identifying effective therapy concepts for advanced stages of the cancer as well as for the development of resection-associated measures. As large-scale, randomised, controlled studies are lacking, the additive therapy concepts after resection do not have a sufficiently scientific basis.The ESPAC-1 study, which included 600 patients, surpassed all previous studies on adjuvant therapy for pancreas cancer.This study has shown,for example, that the most promising adjuvant chemotherapy with 5-fluorouracil and folic acid leads to an equal if not better result than the multimodal regimen.This regimen can be superseded with the use of Gemcitabine, which will be evaluated in the ESPAC-3 study that includes 990 patients from various European countries including Germany, as well as from Canada and Australia. Participation in the large, phase-3 study therefore plays a key role in the continued development of the management of pancreas cancer. More... »

PAGES

191-201

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00104-003-0614-x

DOI

http://dx.doi.org/10.1007/s00104-003-0614-x

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031004895

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/12647075


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antimetabolites, Antineoplastic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Chemotherapy, Adjuvant", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Clinical Trials, Phase III as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Combined Modality Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Controlled Clinical Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Doxorubicin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Folic Acid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hematinics", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Leucovorin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Mitoxantrone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Multicenter Studies as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoadjuvant Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pancreatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quality of Life", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiotherapy Dosage", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Randomized Controlled Trials as Topic", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Time Factors", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "J.P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Raraty", 
        "givenName": "M. G.T.", 
        "id": "sg:person.014701673553.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014701673553.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "P.", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.10025.36", 
          "name": [
            "Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hickey", 
        "givenName": "H.", 
        "id": "sg:person.0717644314.43", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717644314.43"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stocken", 
        "givenName": "D.D.", 
        "id": "sg:person.0750176774.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750176774.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB", 
          "id": "http://www.grid.ac/institutes/grid.6572.6", 
          "name": [
            "CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dunn", 
        "givenName": "J. A.", 
        "id": "sg:person.013255577102.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013255577102.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chirurgische Universit\u00e4tsklinik,Ruprecht-Karls-Universit\u00e4t Heidelberg, DE", 
          "id": "http://www.grid.ac/institutes/grid.7700.0", 
          "name": [
            "Chirurgische Universit\u00e4tsklinik,Ruprecht-Karls-Universit\u00e4t Heidelberg, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Friess", 
        "givenName": "H.", 
        "id": "sg:person.01332350622.56", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332350622.56"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chirurgische Universit\u00e4tsklinik,Ruprecht-Karls-Universit\u00e4t Heidelberg, DE", 
          "id": "http://www.grid.ac/institutes/grid.7700.0", 
          "name": [
            "Chirurgische Universit\u00e4tsklinik,Ruprecht-Karls-Universit\u00e4t Heidelberg, DE"
          ], 
          "type": "Organization"
        }, 
        "familyName": "B\u00fcchler", 
        "givenName": "M.W.", 
        "id": "sg:person.07610347412.52", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07610347412.52"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2003-03", 
    "datePublishedReg": "2003-03-01", 
    "description": "Recent advances have been made in the treatment of pancreas cancer.Specialized pancreas centres have reported an increasing rate of resections with reduced postoperative mortality. On account of the highly aggressive nature of pancreas cancer, there is a great challenge in identifying effective therapy concepts for advanced stages of the cancer as well as for the development of resection-associated measures. As large-scale, randomised, controlled studies are lacking, the additive therapy concepts after resection do not have a sufficiently scientific basis.The ESPAC-1 study, which included 600 patients, surpassed all previous studies on adjuvant therapy for pancreas cancer.This study has shown,for example, that the most promising adjuvant chemotherapy with 5-fluorouracil and folic acid leads to an equal if not better result than the multimodal regimen.This regimen can be superseded with the use of Gemcitabine, which will be evaluated in the ESPAC-3 study that includes 990 patients from various European countries including Germany, as well as from Canada and Australia. Participation in the large, phase-3 study therefore plays a key role in the continued development of the management of pancreas cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s00104-003-0614-x", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1446215", 
        "issn": [
          "2731-6971", 
          "2731-698X"
        ], 
        "name": "Die Chirurgie", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "3", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "74"
      }
    ], 
    "keywords": [
      "pancreas cancer", 
      "therapy concepts", 
      "phase 3 study", 
      "rate of resection", 
      "use of gemcitabine", 
      "multimodal regimen", 
      "postoperative mortality", 
      "adjuvant chemotherapy", 
      "adjuvant therapy", 
      "pancreas center", 
      "aggressive nature", 
      "advanced stage", 
      "cancer", 
      "folic acid", 
      "resection", 
      "regimen", 
      "patients", 
      "Pankreaskarzinoms", 
      "previous studies", 
      "chemotherapy", 
      "gemcitabine", 
      "therapy", 
      "mortality", 
      "study", 
      "key role", 
      "treatment", 
      "recent advances", 
      "continued development", 
      "scientific basis", 
      "European countries", 
      "management", 
      "development", 
      "center", 
      "role", 
      "measures", 
      "rate", 
      "acid", 
      "use", 
      "advances", 
      "stage", 
      "participation", 
      "countries", 
      "Canada", 
      "great challenge", 
      "challenges", 
      "Australia", 
      "basis", 
      "Germany", 
      "nature", 
      "concept", 
      "account", 
      "example"
    ], 
    "name": "Adjuvante und additive Therapie beim Pankreaskarzinom", 
    "pagination": "191-201", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031004895"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00104-003-0614-x"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "12647075"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00104-003-0614-x", 
      "https://app.dimensions.ai/details/publication/pub.1031004895"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-09-02T15:50", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220902/entities/gbq_results/article/article_377.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s00104-003-0614-x"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00104-003-0614-x'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00104-003-0614-x'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00104-003-0614-x'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00104-003-0614-x'


 

This table displays all metadata directly associated to this object as RDF triples.

276 TRIPLES      20 PREDICATES      105 URIs      97 LITERALS      34 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00104-003-0614-x schema:about N195d28a796ac4c03ad2f345de889b29f
2 N1ab4d952100942a8b46750757835d69c
3 N1ad178da189c47b0b5dc1fe1ef1f9b29
4 N1b66be4b4ee14541945568775319fdd7
5 N1f7fa4162f13413d8595448be4cb2dc7
6 N20cabc9870304f7da0fd8aab566b4d62
7 N257a405f7d6340358989841e110710cf
8 N2a475317a5ca4cb79740ea4cc3504c7a
9 N2da4e1bf3a084706a026b4c3f0d5e7f3
10 N2dc0d352f0b644b38de9f00c7e29a934
11 N4f2b1e3174284cd18a40a4d0d8b3e11a
12 N5d99b549949842ffb8e213de156825ac
13 N701781de868741069c46de6e4e080d35
14 N7c071c0a354f4c7eacc3fbf0bc476de3
15 N804e1e265b484369a0a953b43f2a1cb0
16 N8bfe6d5364324b1ebb647e318a930253
17 N8d50342fd72248cd8dec7aa423dd20d6
18 N9af1b626a40540e4951a0033ff48a70f
19 N9bd7d45a13634c0199c74a8aa5706fdb
20 Na7c6230ca2364e478eaeeb2385bb635b
21 Naef65a1fd8f04f258e1993386073ad12
22 Nb0c011359dae4258b02f02bcbbe42f1d
23 Nc21cba9dc3f3426d9922ae7d80f9fa3f
24 Nc3824417ddb54a428260f5467be7145f
25 Nde02a365d1fa40e5ad2241d1ef3c5dec
26 Ne5dee5d896fe4c388915df50b2193e44
27 Nfba262e17691415fa45aa4b45b9c5fdb
28 anzsrc-for:11
29 anzsrc-for:1112
30 schema:author Na7b29d53ea0b4e80961e0ef10f34024c
31 schema:datePublished 2003-03
32 schema:datePublishedReg 2003-03-01
33 schema:description Recent advances have been made in the treatment of pancreas cancer.Specialized pancreas centres have reported an increasing rate of resections with reduced postoperative mortality. On account of the highly aggressive nature of pancreas cancer, there is a great challenge in identifying effective therapy concepts for advanced stages of the cancer as well as for the development of resection-associated measures. As large-scale, randomised, controlled studies are lacking, the additive therapy concepts after resection do not have a sufficiently scientific basis.The ESPAC-1 study, which included 600 patients, surpassed all previous studies on adjuvant therapy for pancreas cancer.This study has shown,for example, that the most promising adjuvant chemotherapy with 5-fluorouracil and folic acid leads to an equal if not better result than the multimodal regimen.This regimen can be superseded with the use of Gemcitabine, which will be evaluated in the ESPAC-3 study that includes 990 patients from various European countries including Germany, as well as from Canada and Australia. Participation in the large, phase-3 study therefore plays a key role in the continued development of the management of pancreas cancer.
34 schema:genre article
35 schema:isAccessibleForFree false
36 schema:isPartOf N35a9e84c1a2a4c4a82c48333f10b124c
37 N7a498e9c9014419e84e4b45c7405d9a1
38 sg:journal.1446215
39 schema:keywords Australia
40 Canada
41 European countries
42 Germany
43 Pankreaskarzinoms
44 account
45 acid
46 adjuvant chemotherapy
47 adjuvant therapy
48 advanced stage
49 advances
50 aggressive nature
51 basis
52 cancer
53 center
54 challenges
55 chemotherapy
56 concept
57 continued development
58 countries
59 development
60 example
61 folic acid
62 gemcitabine
63 great challenge
64 key role
65 management
66 measures
67 mortality
68 multimodal regimen
69 nature
70 pancreas cancer
71 pancreas center
72 participation
73 patients
74 phase 3 study
75 postoperative mortality
76 previous studies
77 rate
78 rate of resection
79 recent advances
80 regimen
81 resection
82 role
83 scientific basis
84 stage
85 study
86 therapy
87 therapy concepts
88 treatment
89 use
90 use of gemcitabine
91 schema:name Adjuvante und additive Therapie beim Pankreaskarzinom
92 schema:pagination 191-201
93 schema:productId N579875a6dfba489c87ad7e347d6587bf
94 N5c4d455b62d14056b8571d6330566905
95 N73bffef6f6354127a7c90a4dc6ba9322
96 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031004895
97 https://doi.org/10.1007/s00104-003-0614-x
98 schema:sdDatePublished 2022-09-02T15:50
99 schema:sdLicense https://scigraph.springernature.com/explorer/license/
100 schema:sdPublisher Nc2decfc176844aac953a6180d8aa6d8f
101 schema:url https://doi.org/10.1007/s00104-003-0614-x
102 sgo:license sg:explorer/license/
103 sgo:sdDataset articles
104 rdf:type schema:ScholarlyArticle
105 N075c1c863aac4b398bed96e58949f861 rdf:first sg:person.0717644314.43
106 rdf:rest N9cc2ef16f65648a8987ca90c1578f898
107 N07d5814665cb42908699c01ecf94142c rdf:first sg:person.07372440237.86
108 rdf:rest N075c1c863aac4b398bed96e58949f861
109 N195d28a796ac4c03ad2f345de889b29f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Multicenter Studies as Topic
111 rdf:type schema:DefinedTerm
112 N1ab4d952100942a8b46750757835d69c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Retrospective Studies
114 rdf:type schema:DefinedTerm
115 N1ad178da189c47b0b5dc1fe1ef1f9b29 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Deoxycytidine
117 rdf:type schema:DefinedTerm
118 N1b66be4b4ee14541945568775319fdd7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Chemotherapy, Adjuvant
120 rdf:type schema:DefinedTerm
121 N1d7c045387c94ae5a58ab3230a65be41 rdf:first sg:person.07610347412.52
122 rdf:rest rdf:nil
123 N1f7fa4162f13413d8595448be4cb2dc7 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Controlled Clinical Trials as Topic
125 rdf:type schema:DefinedTerm
126 N20cabc9870304f7da0fd8aab566b4d62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Mitoxantrone
128 rdf:type schema:DefinedTerm
129 N257a405f7d6340358989841e110710cf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Clinical Trials, Phase III as Topic
131 rdf:type schema:DefinedTerm
132 N2a475317a5ca4cb79740ea4cc3504c7a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Female
134 rdf:type schema:DefinedTerm
135 N2da4e1bf3a084706a026b4c3f0d5e7f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Doxorubicin
137 rdf:type schema:DefinedTerm
138 N2dc0d352f0b644b38de9f00c7e29a934 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Clinical Trials as Topic
140 rdf:type schema:DefinedTerm
141 N35a9e84c1a2a4c4a82c48333f10b124c schema:volumeNumber 74
142 rdf:type schema:PublicationVolume
143 N4f2b1e3174284cd18a40a4d0d8b3e11a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Hematinics
145 rdf:type schema:DefinedTerm
146 N579875a6dfba489c87ad7e347d6587bf schema:name pubmed_id
147 schema:value 12647075
148 rdf:type schema:PropertyValue
149 N5c4d455b62d14056b8571d6330566905 schema:name dimensions_id
150 schema:value pub.1031004895
151 rdf:type schema:PropertyValue
152 N5d99b549949842ffb8e213de156825ac schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Neoadjuvant Therapy
154 rdf:type schema:DefinedTerm
155 N701781de868741069c46de6e4e080d35 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Antineoplastic Agents
157 rdf:type schema:DefinedTerm
158 N73bffef6f6354127a7c90a4dc6ba9322 schema:name doi
159 schema:value 10.1007/s00104-003-0614-x
160 rdf:type schema:PropertyValue
161 N7a498e9c9014419e84e4b45c7405d9a1 schema:issueNumber 3
162 rdf:type schema:PublicationIssue
163 N7c071c0a354f4c7eacc3fbf0bc476de3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
164 schema:name Fluorouracil
165 rdf:type schema:DefinedTerm
166 N804e1e265b484369a0a953b43f2a1cb0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Combined Modality Therapy
168 rdf:type schema:DefinedTerm
169 N8bfe6d5364324b1ebb647e318a930253 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
170 schema:name Radiotherapy Dosage
171 rdf:type schema:DefinedTerm
172 N8d50342fd72248cd8dec7aa423dd20d6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Antimetabolites, Antineoplastic
174 rdf:type schema:DefinedTerm
175 N9af1b626a40540e4951a0033ff48a70f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Neoplasm Recurrence, Local
177 rdf:type schema:DefinedTerm
178 N9bd7d45a13634c0199c74a8aa5706fdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Male
180 rdf:type schema:DefinedTerm
181 N9cc2ef16f65648a8987ca90c1578f898 rdf:first sg:person.0750176774.36
182 rdf:rest Nf51c694691a14040a665632cede6f5dd
183 Na7b29d53ea0b4e80961e0ef10f34024c rdf:first sg:person.0750565077.18
184 rdf:rest Nd6fac01aca4a4c28a5f5f30fdd2a8b6c
185 Na7c6230ca2364e478eaeeb2385bb635b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Time Factors
187 rdf:type schema:DefinedTerm
188 Naef65a1fd8f04f258e1993386073ad12 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Folic Acid
190 rdf:type schema:DefinedTerm
191 Nb0c011359dae4258b02f02bcbbe42f1d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Quality of Life
193 rdf:type schema:DefinedTerm
194 Nc21cba9dc3f3426d9922ae7d80f9fa3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Surveys and Questionnaires
196 rdf:type schema:DefinedTerm
197 Nc2decfc176844aac953a6180d8aa6d8f schema:name Springer Nature - SN SciGraph project
198 rdf:type schema:Organization
199 Nc3824417ddb54a428260f5467be7145f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Pancreatic Neoplasms
201 rdf:type schema:DefinedTerm
202 Nc3ade3ec19794caba2539f1c40581d3a rdf:first sg:person.01332350622.56
203 rdf:rest N1d7c045387c94ae5a58ab3230a65be41
204 Nd6fac01aca4a4c28a5f5f30fdd2a8b6c rdf:first sg:person.014701673553.45
205 rdf:rest N07d5814665cb42908699c01ecf94142c
206 Nde02a365d1fa40e5ad2241d1ef3c5dec schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Leucovorin
208 rdf:type schema:DefinedTerm
209 Ne5dee5d896fe4c388915df50b2193e44 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
210 schema:name Humans
211 rdf:type schema:DefinedTerm
212 Nf51c694691a14040a665632cede6f5dd rdf:first sg:person.013255577102.44
213 rdf:rest Nc3ade3ec19794caba2539f1c40581d3a
214 Nfba262e17691415fa45aa4b45b9c5fdb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
215 schema:name Randomized Controlled Trials as Topic
216 rdf:type schema:DefinedTerm
217 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
218 schema:name Medical and Health Sciences
219 rdf:type schema:DefinedTerm
220 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
221 schema:name Oncology and Carcinogenesis
222 rdf:type schema:DefinedTerm
223 sg:journal.1446215 schema:issn 2731-6971
224 2731-698X
225 schema:name Die Chirurgie
226 schema:publisher Springer Nature
227 rdf:type schema:Periodical
228 sg:person.013255577102.44 schema:affiliation grid-institutes:grid.6572.6
229 schema:familyName Dunn
230 schema:givenName J. A.
231 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013255577102.44
232 rdf:type schema:Person
233 sg:person.01332350622.56 schema:affiliation grid-institutes:grid.7700.0
234 schema:familyName Friess
235 schema:givenName H.
236 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01332350622.56
237 rdf:type schema:Person
238 sg:person.014701673553.45 schema:affiliation grid-institutes:grid.10025.36
239 schema:familyName Raraty
240 schema:givenName M. G.T.
241 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014701673553.45
242 rdf:type schema:Person
243 sg:person.0717644314.43 schema:affiliation grid-institutes:grid.10025.36
244 schema:familyName Hickey
245 schema:givenName H.
246 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717644314.43
247 rdf:type schema:Person
248 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.10025.36
249 schema:familyName Ghaneh
250 schema:givenName P.
251 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
252 rdf:type schema:Person
253 sg:person.0750176774.36 schema:affiliation grid-institutes:grid.6572.6
254 schema:familyName Stocken
255 schema:givenName D.D.
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750176774.36
257 rdf:type schema:Person
258 sg:person.0750565077.18 schema:affiliation grid-institutes:grid.10025.36
259 schema:familyName Neoptolemos
260 schema:givenName J.P.
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
262 rdf:type schema:Person
263 sg:person.07610347412.52 schema:affiliation grid-institutes:grid.7700.0
264 schema:familyName Büchler
265 schema:givenName M.W.
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07610347412.52
267 rdf:type schema:Person
268 grid-institutes:grid.10025.36 schema:alternateName Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB
269 schema:name Department of Surgery, Liverpool University, Liverpool, United Kingdom, GB
270 rdf:type schema:Organization
271 grid-institutes:grid.6572.6 schema:alternateName CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB
272 schema:name CRUK Institute for Cancer Studies,Birmingham, United Kingdom, GB
273 rdf:type schema:Organization
274 grid-institutes:grid.7700.0 schema:alternateName Chirurgische Universitätsklinik,Ruprecht-Karls-Universität Heidelberg, DE
275 schema:name Chirurgische Universitätsklinik,Ruprecht-Karls-Universität Heidelberg, DE
276 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...